Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity
Name
mbio.01647-22.pdf
Description
Published version
Size
2.28 MB
Format
Adobe PDF
Checksum (MD5)
eaf1a4eab6ef5d0246491696fd90bcc8
Author(s)
Bowman, Kathryn A
Stein, Daniel
Shin, Sally
Ferbas, Kathie G
Tobin, Nicole H
Mann, Colin
Fischinger, Stephanie
Ollmann Saphire, Erica
Lauffenburger, Douglas
Rimoin, Anne W
Date Issued
2022
Journal
mBio
Publisher
American Society for Microbiology
Citation
Bowman, Kathryn A, Stein, Daniel, Shin, Sally, Ferbas, Kathie G, Tobin, Nicole H et al. 2022. "Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity." mBio, 13 (5).
Version
Final published version
Abstract
Recent data indicates improved immunity to SARS-CoV-2 in individuals who experience a combination of two mRNA vaccine doses and infection, “hybrid immunity,” compared to individuals who receive vaccination or experience infection alone. While previous infection accelerates the vaccine-induced immune response following the first dose of mRNA vaccination, subsequent doses demonstrate negligible increases in antibody titers or T cell immunity.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1128/MBIO.01647-22
